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Streptococcus pneumoniae (pneumococcus) is a major human pathogen and
commensal organism of the nasopharynx. A major virulence factor of the pneumococcus
is the cholesterol dependent, pore forming cytolysin pneumolysin. This toxin acts
extracellularly, but the mechanism of release has not been well elucidated. Despite being
a catalase negative organism, the pneumococcus produces up to millimolar
concentrations of hydrogen peroxide through the activity of pyruvate oxidase. In all
strains analyzed, deletion of the pyruvate oxidase gene yielded a significant reduction in
the amount of PLY observed in the supernatant via western blot. A single strain, WU2
was also observed to have a significant (p<.05) reduction in the amount of PLY observed
in the supernatant when treated with extracellular catalase. Furthermore, a significant
correlation between hydrogen peroxide production and PLY release was observed in a
panel of 15 clinical isolates.
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LITERATURE REVIEW

1.1

Streptococcus pneumoniae and disease burden
Streptococcus pneumoniae is a gram-positive, catalase negative major human

pathogen worldwide, as it is the causative agent of otitis media, bacteremia, septicemia,
pneumonia, and meningitis (1). Additionally, this pathogen is the leading cause of death
for children under the age of five worldwide (2, 3). Diseases caused by pneumococcus,
such as bacterial pneumonia, also significantly impact immunocompromised populations
including the elderly (4). Pneumococcal disease carries a significant economic burden
due to the high costs associated with antibiotic resistance, estimated to be responsible for
233 million dollars in healthcare expenses and is further magnified if parental visits to
pediatricians are considered, as pneumococcus is the most common etiological agent of
acute otitis media (5). For instance, healthcare costs from acute otitis media in the United
States have been estimated to range from approximately 3 billion dollars to potentially as
high as 6 billion dollars (6, 7). Pneumococcus has also been observed to have a
synergistic effect upon coinfection with the influenza virus, as viral infection increases
bacterial counts, indicating that a significant portion of morbidity and mortality resulting
from influenza infection could be attributable to pneumococcal disease (8, 9).
Despite this major impact on human health, however, the organism is a common
commensal organism found in the nasopharynx, with carriage rates of up to 70%,
1

depending on the population (10). The typical process of disease progression involves
transfer of bacteria to the lower respiratory system from the nasopharynx, thereby leading
to pneumonia. From there, the organism can enter the bloodstream causing bacteremia
and eventually cross the blood brain barrier to cause meningitis (2, 3, 11).
The pneumococcus possesses an arsenal of virulence factors capable of enhancing
its pathogenicity in the host. The pneumococcus has over 90 different serotypes of antiphagocytic polysaccharide capsules that allow it to thwart the innate immune system,
with differences in strain virulence based on capsule type (12, 13). These capsule types
vary in composition and size, accounting for a great deal of variability among strains
producing different capsule serotypes (14). Additionally, the pneumococcus possesses a
number of surface proteins, including PspA, neuraminidase, hyaluronidase, that are
capable of triggering an immune response from the host (15–18).
Currently, there are two types of vaccines commercially available for the
prevention of pneumococcal disease: 1) a conjugated polysaccharide vaccine conferring
immunity to 7-13 capsule types, approved for children and infants; 2) a capsular
polysaccharide vaccine conferring immunity to 23 different strains that imparts immunity
in adults (19–21). While the introduction of these vaccines has led to a reduction in the
amount of pneumococcal disease observed in at-risk groups, serotype replacement is
increasing (22–25).
1.2

Pneumolysin
Streptococcus pneumoniae possesses a number of virulence factors that augment

its pathogenicity. Among these virulence factors is the 53-kDa cholesterol-dependent
pore-forming cytolysin (CDC), pneumolysin (PLY) (26). PLY is found to be a major
2

virulence factor, being diagnostic in the cerebrospinal fluid for meningitis, reducing
ciliary beat frequency in the lungs, and attenuating the virulence of the organism in vivo
when deleted from the chromosome (27–30). Strain-based variations in the amount of
PLY produced by pneumococcus have been identified in the literature as well (31).
Additionally, PLY has been found to activate the classical pathway of complement and
interact with Toll Like Receptor 4 (TLR4) (27, 29). Production of PLY has also been
observed to be significant for pneumococcal biofilm formation, an important step in
colonization of the nasopharynx, with ply- mutants less able to form biofilms than wild
type (28, 32, 33).
Toxoid versions of PLY have been proposed as potential protein-based vaccine
antigen candidates to replace the current capsular vaccines with one that would ideally be
universal for a conserved domain of the protein (34–36). The mechanism through which
PLY forms pores is well elucidated, with the toxin binding to cholesterol in the cell
membrane, followed by oligomerization to form a pre-pore complex on the surface of the
eukaryotic cell. After which a pore approximately 260 angstroms in diameter is formed,
allowing for loss of intracellular proteins, ions and other molecules from the cell (37–39).
Pneumolysin is the only known cholesterol-dependent cytolysin that lacks a Nterminal secretion sequence for release into the extracellular space via the Sec-dependent
pathway of protein secretion. Additionally, it lacks any sequence for any other known
secretion pathway (26, 40). Other members of the CDC family, such as listeriolysin O in
Listeria monocytogenes and perfringolysin O in Clostridium perfringens have been
demonstrated to be released via the Sec-dependent pathway (41–43). Interestingly, it has
been published that when the Sec-dependent export signal is added back to PLY in the
3

pneumococcus, it is incapable of being secreted, indicating that PLY may actually be
incompatible with the secretion pathway (44). In spite of this lack of a secretion signal,
the protein is still found in the extracellular space (26, 28). A number of mechanisms
through which PLY can be released to the extracellular space have been identified. The
major mechanism for PLY liberation is by autolysis via the activity of the autolytic cell
wall amidase lytA (45). Through this mechanism, the cell wall is broken down and
intracellular products are released to the extracellular space. Another mechanism that has
been identified is the fratricide of other pneumococci induced by competence, or the
natural uptake of genetic material by the pneumococcus (46). Fratricide releases PLY due
to the killing of non-competent pneumococci by competent pneumococci resulting in
uptake of the released DNA. This process of killing also releases PLY to the extracellular
space. Interestingly however, is that the release of PLY has been observed in mutants
that lack the lytA gene (47). This indicates that some aspect of PLY release is not
attributable to the activity of lytA, as PLY is still seen in the extracellular space of
mutants lacking that gene, but the specific mechanism related to this release has not been
identified. Additionally, association of active PLY with the cell wall of pneumococcus
that is unrelated to the activity of lytA has also been demonstrated in a panel of strains
(48).
1.3

Pneumococcal hydrogen peroxide
Although Streptococcus pneumoniae is a catalase negative organism, it is still

observed to produce up to millimolar concentrations of hydrogen peroxide (49).
Hydrogen peroxide is produced through the aerobic metabolism of pyruvate via the
enzyme pyruvate oxidase (SpxB) converting pyruvate to lactate, producing CO2 and
4

H2O2 as metabolic byproduct (49). This metabolism only occurs in an aerobic
environment (50, 51). While this hydrogen peroxide produced by the pneumococcus is
toxic to the bacterial cell at elevated concentrations, it is still required for the organism to
exhibit virulence in vivo and it is found to confer an advantage to survival in colonization
by the pneumococcus (51, 52). Pneumococcal H2O2 has a significant impact on the host,
as it is capable of causing neuronal cell death during meningitis, necrosis and apoptosis
of neutrophils, and necrosis and apoptosis of alveolar cells (52–54, 59). The production
of hydrogen peroxide also aids the pneumococcus in competing with other organisms in
the relatively oxygen-rich nasopharynx. It has been demonstrated that pneumococcal
H2O2 confers an advantage when considering competition in the nasopharynx with other
inhabitants such as Haemophilus influenza and Staphylococcus aureus that are more
sensitive to stress from H2O2 (55, 56). Additional work indicates that ∆spxB mutants of
pneumococcus are outcompeted by spxB+ pneumococci in an in vivo rat model, lending
further evidence to pyruvate oxidase conferring a competitive advantage as
pneumococcal H2O2 was lethal to the competing ∆spxB mutant (57). Usage of pyruvate
oxidase also appears to confer protection from killing by H2O2 making the organism
more resistant to killing than other inhabitants of the nasophayrnx (49, 56, 57).
Of note is the fact that pyruvate oxidase is not the sole pathway through which
hydrogen peroxide can be produced in the pneumococcus. The organism can also
produce hydrogen peroxide through the activity of lactate oxidase (LctO) (49, 58). This
pathway of hydrogen peroxide production has been studied less than the better-known
pathway involving pyruvate oxidase. During glucose metabolism, up to 75% of the
pyruvate that is processed by the organism is converted into lactate. In this environment,
5

lactate oxidase is very important for converting lactate back to pyruvate for continued
ATP production when pyruvate production via glycolysis has slowed due to reductions in
the amount of glucose available to the organism (49). However, a great deal of the H2O2
produced by the pneumococcus can likely be attributed to the activity of pyruvate oxidase
(49, 50, 52).
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CHAPTER II
DETERMINATION OF THE EXTENT TO WHICH PYRUVATE OXIDASE
IMPACTS PNEUMOLYSIN RELEASE

2.1

Introduction
Streptococcus pneumoniae is a commensal organism of the nasopharynx that

causes a number of major human diseases such as sinusitis, otitis media, bacteremia,
meningitis, septicemia, and bacterial pneumonia (1, 2). As a major human pathogen, it
has a significant impact upon public health and the economy, causing 3 billion to 6
billion dollars in health care costs as well as lost work from doctors visits related to otitis
media alone (3, 4). Pneumococcus possesses a host of virulence factors including a
variety of pneumococcal surface proteins such as PspA, neuraminidase and an antiphagocytic polysaccharide capsule (5–7). This chapter will focus on two virulence
factors in particular, the toxin pneumolysin (PLY) and the protein pyruvate oxidase
(SpxB).
One of the primary virulence factors of the pneumococcus is PLY, a 53-kDa
member of the cholesterol dependent cytolysin (CDC) family of pore forming toxins (8).
Other members of this family of proteins have been demonstrated to be secreted via the
Sec-dependent pathway in other gram-positive organisms like listeriolysin O in Listeria
monocytogenes and perfringolysin O in Clostridium perfringens. However, it is
interesting to note that this mechanism of transport for PLY does not occur in the
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pneumococcus as it lacks the N-terminal secretion signal required for Sec-dependent
secretion (9–11). Interestingly, however, PLY is still observed in the supernatant of
actively growing cells and exerts its toxic functions extracellularly (8, 12). Furthermore,
differences between strains have been observed for the production of PLY in vitro (23).
The method of secretion of this toxin has been difficult to characterize, although a
number of mechanisms have been identified in the literature. Initially, it was thought that
pneumococcal autolysis through the activity of lytA, an autolytic cell wall amidase that
breaks down the cell wall was essential for releasing PLY into the surrounding space (13,
14). However, release of PLY into the supernatant is still observed in pneumococci
lacking the gene lytA, indicating that the bacterium possesses additional mechanisms for
PLY release (16). A number of other mechanisms have since been identified. One of
which is fratricide of other pneumococci by competent organisms, as pneumococcus is a
naturally competent organism (15). In this process, pneumococci that have become
competent release products that are toxic to non-competent cells. The death of these cells
leads to the release of PLY.
Another major virulence factor of the pneumococcus is the enzyme pyruvate
oxidase, encoded by the spxB gene (17). Although pneumococcus is a catalase negative
organism, it is capable of producing up to millimolar concentrations of hydrogen
peroxide (H2O2) as a byproduct when it performs glycolysis reactions in an aerobic
environment, making its production oxygen-dependent, as the organism is a facultative
anaerobe (18). While this H2O2 is toxic to the pneumococcus in higher concentrations,
SpxB appears to confer an advantage to the organism in resistance to H2O2 killing and in
vivo virulence, due to greater ATP depletion in spxB negative mutants (19, 20).
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Additionally, pyruvate oxidase gives the pneumococcus a competitive advantage against
other organisms when colonizing the nasopharynx as it has a higher tolerance for H2O2
than other inhabitants like H. influenzae or S. aureus (21, 22). In addition to toxicity to
other inhabitants of the nasopharynx, pneumococcal H2O2 has been observed to have
deleterious effects on host cells as well. Published work, along with unpublished work
from our lab indicates that pneumococcal H2O2 causes DNA damage to host cells (32).
Additionally, it causes damage to alveolar cells and host immune cells (24, 25). Despite
the lethal effect of H2O2 on the pneumococcus, a link between pyruvate oxidase activity
and PLY release has not been reported. Based on the lethal impact of H2O2 on the
pneumococcus, we decided to investigate the impact of H2O2 production upon PLY
release.
In this study, we identified a significant (p<0.005) reduction in the amount of
PLY released into the supernatant of isogenic ∆spxB mutants of strains WU2 and
AW267, considered high PLY releasing strains. This relationship was also seen with
strains T4 (p<0.005), and T4R (p<0.05) with both demonstrating a significant reduction
in the amount of PLY observed when spxB is removed. Additionally, a significant
(p<0.05) correlation between H2O2 production and PLY release was observed in a panel
of clinical isolates obtained from St. Jude’s Children’s Research Hospital. It was
demonstrated by qRT-PCR that the reduction in PLY was due to differences in release,
and could not be attributed to differences in transcription of ply when spxB is removed.
Additionally, it was demonstrated that removal of exogenous hydrogen peroxide by the
use of catalase, an H2O2 degrading enzyme, led to a significant reduction in PLY released
from WU2. Furthermore, we tested the hypothesis that H2O2 causes PLY release by
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causing a reduction in membrane potential, making the cellular membrane leaky, with
preliminary data using the fluorometric dye, JC-1, indicating that this may be the case.
Finally, we confirmed that the reduction in PLY release is not attributable to differences
in autolysis between the mutant and wild type.
2.2
2.2.1

Materials and Methods
Strains used
The wild-type strains used for this study were high PLY-releasing strains AW267

and WU2, and low PLY-releasing strains T4 and T4R (unencapsulated mutant of T4).
Isogenic ∆spxB mutants were generated in each of these strains by replacing the gene
with an erythromycin cassette for selection purposes. Where indicated, these strains were
treated with 10µg of catalase to neutralize extracellular H2O2. Clinical significance was
investigated through the use of a panel of 21 clinical isolates obtained from St. Jude’s
Children’s Research Hospital.
2.2.2

Growth of strains
Bacterial strains were grown to a mid-log phase (OD600 0.5) in Todd Hewitt

media supplemented with 0.5% yeast extract (THY) in a 37˚C water bath in 5 mL
cultures. Upon reaching the desired OD, 1 mL of bacterial culture was centrifuged for 5
minutes at 15,000 rpm. After centrifugation, the supernatant was removed and 500µL
was filtered over a 0.2µm polyethersulfone (PES) (Celltreat) filter to remove any
remaining bacteria not pelleted during centrifugation. After obtaining supernatants, H2O2
concentrations were calculated using a colorimetric peroxide detection assay (Pierce).
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2.2.3

Treatment with hydrogen peroxide
T4R∆spxB was supplemented with exogenous H2O2 (500µM) for one hour on ice.

Serial dilution plate counts were made before and after treatment to ensure that
concentrations were not lethal to the organism.
2.2.4

Western blot method
After obtaining bacterial supernatants, PLY was analyzed through the use of SDS-

PAGE western blotting. Four microliters of 5X Laemmi buffer was added to 20µL of
bacterial supernatant and heated at 99˚C for 5 minutes in a thermocycler. After boiling
the protein for 10 mins, 20µL of denatured sample was loaded onto a 10% SDS-PAGE
gel. The gel was allowed to elute via electrophoresis until the dye front had entirely
eluted (BioRad). BR Spectra (Thermo Scientific) ladder was used to determine protein
size on the gel. The proteins were then transferred to a PVDF membrane (Millipore)
utilizing the semi-dry transfer method for 35 minutes. Following this transfer of proteins,
the membrane was blocked in Tris Buffered Saline+0.1% Tween (TTBS) with 5% milk
for 30 minutes while agitating. Following the blocking step, the blot was probed
overnight at 4˚C with 1:200 rabbit anti-PLY polyclonal serum diluted in 5% milk +
TTBS. Following overnight probing of the membrane, it was then washed in TTBS 4
times for 5 minutes each while agitating. Following the wash of the membrane, the blot
was then probed with a secondary goat anti-rabbit IgG horseradish peroxidase-conjugated
antibody at a dilution of 1:2500 (BioRad) for 1 hour at room temperature while agitating.
Following probing with the secondary antibody, it was then washed with TTBS 4 times, 5
minutes each while agitating. The blot was developed using enhanced chemiluminescent
substrate (ECL) (Pierce) for 1 minute. Following the application of the substrate, the blot
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was exposed to radiography film for 15 seconds and developed. The density of the PLY
band was determined using ImageJ software (NIH) to make a relative determination of
PLY release to the supernatant.
2.2.5

Dot blot method
The amount of PLY released from clinical supernatants, was quantitated via dot

blot. A PVDF membrane was placed in a 96-well vacuum dot blotting apparatus
(BioRad) and the wells were washed with 100µL of phosphate buffered saline (PBS)
twice. A known amount of recombinant PLY at a concentration of 1.2 mg/mL was
diluted down to 500 ng/mL and then serially diluted 1:2 into PBS 8 times to yield a
standard curve that could be used to interpolate protein concentrations from supernatants.
Forty microliters of each protein standard was applied to a PVDF membrane in a vacuum
dot blotting apparatus (BioRad). One-hundred microliters of clinical supernatant was
applied to the membrane as well. The samples were allowed to filter via gravity on the
membrane for 45 minutes at room temperature without any application of vacuum. After
the gravity filtration of the clinical proteins, the vacuum was then applied gently. After
vacuum filtration of the proteins, the blot was again washed with 100µL of PBS per well.
Following the PBS wash of the membrane, it was then blocked with 5% milk in TTBS
for 30 minutes while agitating. After blocking the membrane, 10 mL of 1:200 rabbit anti
PLY polyclonal serum was applied to the blot overnight at 4˚C. After probing with the
primary, the blot was then washed 4 times 5 minutes each using TTBS while agitating.
Following the wash of the membrane, 10 mL of 1:2500 goat anti rabbit IgG antibody in
5% milk+TTBS was applied to the blot for 1 hour at room temperature while agitating.
Following probing the membrane with the secondary antibody, the blot was again washed
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4 times 5 minutes each using TTBS. After washing the blot, ECL substrate was applied to
the blot for 1 minute. After applying the substrate, the blot was exposed to film for 15
seconds. The density of the dots was determined using ImageJ software. The density of
dots of a known concentration used to generate a regression that could be used to
interpolate the unknown clinical protein concentrations. These interpolated values were
normalized to clinical bacterial counts per 100,000 cells. This data was graphed versus
H2O2 produced per 100,000 cells.
2.2.6

Determination of ply fold change
Pneumococcal strains AW267, T4R, WU2, or their isogenic ∆spxB mutants were

grown to an OD of 0.5 in THY. Where indicated, upon reaching OD 0.5, T4R∆spxB was
treated with 500µM hydrogen peroxide for 1 hour on ice, with a control treatment getting
no hydrogen peroxide. This concentration was used as it was found to be non-lethal to the
organism (Appendix 2). Upon reaching this optical density, 2 mL of bacterial culture was
added to 4 mL of RNAprotect (Qiagen) and incubated at room temperature for 5 minutes.
Following this incubation period, 2 mL of this suspension was pelleted at 13,000 rpm for
5 minutes. After centrifugation, the supernatant was removed and the pellet was
then resuspended in 1 mL of cold RNAse free PBS. After resuspending, the bacteria were
once again pelleted for 5 minutes at 13,000 rpm, the supernatant was removed, and the
bacteria were resuspended in 400 µL of RLT lysis buffer (Qiagen). After resuspention of
the bacteria, the cells were then sonicated 3 times for 15 seconds on ice. After sonication,
the sonicated bacteria were added to bead-beating tubes along with 500 µL of zirconium
beads, 700 µL of RLT buffer was also added. The tubes were sealed with parafilm, and
the tubes were loaded into a bead-beating apparatus (BioSpec). The tubes were bead
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beaten for 2 minutes twice, after which the samples were then centrifuged shortly on a
tabletop centrifuge. 700µL of this supernatant was then passed over a QIAshredder
homogenization column (Qiagen) at 13,000 rpm for 30 seconds. 100% ethanol was added
to the homogenized sample. Following this, RNA was extracted from the samples
utilizing the RNeasy RNA purification column with a RNAse free DNAse treatment step
to remove contaminating DNA (Qiagen). The RNA was eluted from the column in 20µL
of RNAse free water. RNA values were obtained via fluorometric analysis utilizing
a Qubit (Life Technologies) and contaminating DNA was detected utilizing the same
apparatus. After which, 50 ng of bacterial RNA were then treated with Maxima reverse
transcriptase enzyme to generate cDNA from the RNA. Quantitative RT-PCR was used
with this cDNA as template following a 1:100 dilution of the cDNA. using a 96 well realtime PCR thermocycler (Applied Biosystems). Fold change of the ply gene was
determined using the ∆∆CT method, using gyrA as an internal housekeeping gene. Fold
change in the isogenic spxB mutant was compared against the wild type in that strain.
2.2.7

Quantitation of pneumococcal membrane potential
Pneumococcal strains T4R, and AW267 and isogenic ∆spxB mutants were grown

to a mid log phase of growth (OD600 0.5) in Todd Hewitt media with 0.5% yeast extract.
One milliliter of bacterial culture was centrifuged 5 minutes at 15,000 rpm, and
resuspended in 500µL of PBS supplemented with 2% sterile glucose. The bacteria were
then incubated 15 minutes at 37˚C. In order to examine the change in pneumococcal
membrane potential upon interaction with H2O2 the JC-1 mitochondrial membrane
potential dye was utilized.
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These glucose-supplemented cells were treated with 5µL of JC-1 and vortexed.
One-hundred microliters of the dyed cells were added to 96 well plates. These cells were
then brought to a total volume of 200µL by adding 100µL of 500 µM, 1 mM, and 2 mM
hydrogen peroxide in PBS, yielding half the concentration indicated. Additionally, 0.1%
sodium deoxycholate was used at a final concentration of 0.05% to act as a positive
control for membrane depolarization. One-hundred microliters of PBS was added to the
non-treated cells to half the concentration of glucose. Fluorescence of these cells was
measured at 485 nm to indicate strong membrane potential, and 530 nm to indicate weak
membrane potential. A ratiometric analysis was performed by calculating the ratio of
strong membrane potential to weak membrane potential over the course of 3 hours at
37˚C.
2.2.8

Assessment of the impact of autolysis upon release
Pneumococcal strain T4R and its isogenic ∆spxB mutant were grown to a mid log

phase of growth (OD600 0.5) in 3 mL of THY. Upon reaching the desired OD, Triton X100 was added to the media in a concentration of 0.1%. Upon adding the Triton, the OD
of the cultures was recorded every 5 minutes for 20 minutes or until the OD of the culture
reached zero. Additionally, a second chemical lysis assay was performed utilizing 0.05%
sodium deoxycholate in the same conditions as the above assay.
Additionally, a fluorometric quantitation of the amount of DNA observed in the
supernatant of T4R and T4R∆spxB was performed utilizing a Qbit fluorometer in order to
utilize an alternate method to ascertain any differences between autolysis between the
mutant and wild type, 2 µL of bacterial supernatant was assayed for DNA content.
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2.2.9

Statistical analysis
A Student’s t test was performed to determine statistical significance of

differences. A P-value less than 0.05 was considered statistically significant. For the
clinical data, a linear regression was performed to determine if a correlation existed
between H2O2 produced and PLY released. A P value less than 0.05 was considered
statistically significant.
2.3
2.3.1

Results and Discussion
Impact of spxB deletion on PLY release
The deletion of spxB from the chromosome caused a significant (p<0.005)

reduction in the amount of PLY released into the supernatant in two of the 4 mutant
strains, when compared to their wild-type counterparts, AW267 (Fig 2.1A), WU2 (Fig
2.1B), and T4 (Fig 2.1C). Additionally, a significant (p<0.05) reduction in PLY release
was also observed in spxB- strains of T4R (Fig 2.1D). This indicates that pyruvate
oxidase plays a role in the release of PLY in these strains. H2O2 values were quantified
for each of the strains and their isogenic mutants (Fig 2.2). These results lends evidence
to the fact that this mechanism of release appears to hold true for a wide range of strains,
which seems to concur with previous findings that there are strain related differences for
PLY production (13).
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Figure 2.1

PLY band densities for wild type and ∆spxB mutants

Supernatants were obtained from all four strains, AW267, WU2, T4, and T4R
along with their respective isogenic ∆spxB mutants. The band density of their PLY band
was quantitated using ImageJ following western blotting of the sterile supernatant.
Significance of p<0.05 is represented by a single asterisk (*), significance of p<0.005 is
represented by two asterisks (**). Each figure represents at least 3 replicate experiments,
plus and minus the standard deviation. Representative PLY bands are shown beneath
each figure.
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Figure 2.2

H2O2 quantification for wild type and ∆spxB mutants

Supernatants obtained from AW267, WU2, T4, T4R, and their respective ∆spxB mutants
were assessed for H2O2 content via colorimetric assay. Data shown is the average of three
independent experiments plus and minus the standard deviation.
2.3.2

Correlation of H2O2 production and PLY release
In order to investigate the clinical relevance of this H2O2 dependent PLY release,

we assessed PLY release and H2O2 production in a panel of 15 clinical isolates. These
data were normalized to cell count in order to account for the potential variation in cell
density at the OD of 0.5. Upon performing a linear regression on the data obtained from a
panel of 15 clinical isolates, a significant correlation (p<0.05, r2=.3167) between PLY
release and H2O2 production per 100,000 bacterial cells was observed (Fig 2.3). Previous
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data collection of unfiltered bacterial supernatants indicated a more significant correlation
between H2O2 production and PLY release (Appendix 1). This potentially indicates that
cell wall association played some role in the correlation, as it was more statistically
significant when bacterial cells were present in the supernatant (26).

Figure 2.3

Correlation of H2O2 vs PLY released in clinical isolates.

An analysis of sterile supernatants of 15 clinical isolates was performed.
Hydrogen peroxide was quantitated for each strain and normalized to cell counts per
100,000 cells. The amount of PLY in the supernatant was quantitated utilizing dot
blotting and also normalized per 100,000 cells. A significant (p<0.05) correlation
(r2=.3167) was observed between H2O2 production and PLY release. (n=15, p<0.05,
r2=.3167)
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2.3.3

Effects of SpxB on ply gene expression.
One potential explanation for the reduction in PLY release is that production of

H2O2 could increase ply gene expression, increasing the amount of PLY observed in the
supernatant of the wild type. In order to investigate this possibility, we quantitated ply
gene expression for wild type and spxB- strains using qRT-PCR. Finally, we investigated
the possibility that exogenous H2O2 could have some impact on ply expression in an
spxB- strain using the same method. The results from the qRT-PCR of WU2 (Fig 2.4A),
AW267 (Fig 2.4B), and T4R (Fig 2.5) indicate that in every case, the ∆spxB is seen to
have upregulation of transcription of ply. In AW267∆spxB, ply transcription of ply 2.83
fold, for WU2∆spxB was upregulated 1.96, and in T4R∆spxB ply expression was found to
be upregulated 2.3 fold. This lends evidence to the hypothesis that the reduction observed
in Figure 2.1 is not attributable to reduction of transcription when spxB is removed from
the chromosome. Furthermore, upon treatment with 500µM H2O2 for 1 hour on ice,
T4R∆spxB (Fig 2.5) exhibited a 1.45 fold upregulation in the ply gene versus T4R∆spxB
with no H2O2 treatment. These data not only demonstrate that hydrogen peroxide is not
contributing to increased ply gene expression, but also that PLY production isn’t
associated with a metabolic byproduct of SpxB. It appears, if anything, SpxB activity
decreases ply expression. Previous literature indicates that environmental conditions have
no significant impact upon PLY transcription when transcription of ply is investigated in
various environments like the blood, lungs and nasopharynx (27).
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Figure 2.4

Fold change of ply gene expression of WU2 and AW267 compared to
respective mutants.

Gene expression in WU2 and its isogenic spxB mutant (Fig 2.4A) and AW267 and its
isogenic spxB mutant (Fig 2.4B) was measured via ∆∆CT. Deletion of spxB in WU2
demonstrates a 1.96 fold upregulation of ply. Upregulation was also seen in
AW267∆spxB where a 2.83 fold upregulation was observed. Data shown is an average of
3 experiments
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Figure 2.5

Fold change of ply in following exogenous H2O2 exposure.

Fold change in ply expression for T4R∆spxB was measured via ∆∆CT following treatment
with 500µM H2O2 additionally, data for untreated T4R∆spxB is shown. A 2.3 fold
upregulation versus the wild type was observed in the untreated mutant, along with a
1.45 fold upregulation in the treated mutant versus wild type. Data shown is an average
of 3 experiments.
2.3.4

Analysis of extracellular hydrogen peroxide
In order to ascertain the impact of extracellular H2O2 versus intracellular H2O2 a

twofold approach was taken. In order to remove extracellular H2O2 from the wild type
pneumococcus, catalase, a H2O2 degrading enzyme was used. Removal of intracellular
hydrogen peroxide was achieved through the deletion of spxB. Upon analyzing these
supernatants via western blot, an interesting effect was seen. A significant (p<0.05)
negative impact upon PLY release in WU2 versus WU2 supplemented with catalase (Fig
2.6A) was observed. However, despite the removal of spxB attenuating the release of
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PLY in all other strains, addition of catalase failed to achieve a significant difference
between wild type and the wild type supplemented with catalase (Fig 2.6B). H2O2 values
for each of the strains and conditions was determined via colorimetric assay (Fig 2.7).
This could indicate that the strain dependent difference as described above, however it
appears that H2O2 acts more extracellularly in WU2. This relationship was further
investigated by supplementing T4R∆spxB with 500µM H2O2 on ice for one hour.
However there was no significant difference between the amount of PLY quantified in
the supernatant by dot blot in the treated samples versus the untreated samples (Fig 2.8).
This further indicates that H2O2 may have an intracellular impact or that the amount of
time that the H2O2 was applied was insufficient to cause release.
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Figure 2.6

Impact of catalase treatment upon PLY band density in wild type and
∆spxB mutants

PLY band densities for strains treated with 10 µg of catalase was determined using
densitometry of western blots of sterile supernatants. Significance of p<0.05 is noted by a
single asterisk (*), significance of p<0.005 is demonstrated by two asterisks (**). Data
shown is from 3 replicate experiments. Representative PLY bands are shown below the
figures.
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Figure 2.7

H2O2 quantitation of wild type and mutants supplemented with catalase

H2O2 values for each strain’s wild type and ∆spxB mutant with and without 10µg of
catalase added was assessed via colorimetric assay. Each figure represents three
independent trials, plus and minus the standard deviation.
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Figure 2.8

PLY quantitation following exogenous treatment with H2O2

T4R∆spxB was grown to an OD of 0.5, placed on ice for 1 hour and either treated with
500µM H2O2 or no treatment. The amount of PLY in the supernatant was quantitated via
dot blot. Analysis of this data indicated no significant impact from incubating T4R∆spxB
with H2O2 Data shown is from 3 duplicate experiments.
2.3.5

Assessment of the impact of autolysis
To determine if differences in autolysis could be causing the reduction in the

amount of PLY observed in the supernatant, three assays were performed. A direct assay,
using 0.1% Triton X-100 or 0.5% sodium deoxycholate to chemically lyse the cells, and
an indirect assay to quantitate the amount of DNA found in sterile filtered supernatants.
Chemical lysis of T4R and T4R∆spxB indicated that there was no difference in autolysis
between the mutant and wild-type (2.9) (Appendix 6). Furthermore, quantitation of the
amount of DNA found in the supernatant also shows no difference between T4R and
T4R∆spxB as well (Appendix 6). This indicates that higher levels of autolysis in the wild
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type strain does not appear to be a good explanation for the increased levels of PLY in
the supernatant of the wild type versus the mutant. This is also supported by the fact that
the bacterial counts between mutant and wild type are not significantly different at OD
0.5 (Appendix 4).

Figure 2.9

Difference in autolysis between T4R and T4R∆spxB

Assessment of the lysis of T4R and T4R∆spxB over 20 minutes at OD 0.5 shows no
significant difference between the mutant and wild type with respect to autolysis. Data
shown is from 3 duplicate experiments.
2.4

Conclusion
The data presented in this chapter makes a strong case for the production of

hydrogen peroxide by pyruvate oxidase activity allowing for the release of PLY in vitro.
Initially to investigate the impact of pyruvate oxidase on PLY release, we examined a
panel of wild type pneumococcal strains, WU2, AW267, T4, and T4R and their isogenic
∆spxB mutants to determine the extent to which H2O2 impact PLY release. Removal of
pyruvate oxidase in strains WU2, AW267, and T4 causes a significant (p<0.005)
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reduction in the amount of PLY detected in the supernatant by western blot. Additionally,
this trend is seen in T4R, with a significant (P<0.05) reduction observed when spxB is
deleted. This indicates that the effect appears to be general across strains, lending strong
evidence to support the hypothesis that spxB activity leads to PLY release.
The case for H2O2 causing PLY release is further strengthened by the presentation
of a statistically significant correlation (p<.05) that exists between H2O2 production and
PLY release in a panel of 15 clinical isolates. This indicates that this relationship appears
to hold true in a clinically relevant sampling of pneumococcus and could relate to the
strain differences in PLY production and H2O2 production. Previous data indicated a
more statistically significant correlation when bacterial supernatants were unfiltered, this
could potentially indicate a role for the association of pneumolysin with the cell wall of
the pneumococcus leading to a deleterious impact on the correlation (26). However, this
data supports the data shown for the removal of spxB.
Finally, qRT-PCR data indicates that the reduction in PLY that has been observed
in strains WU2 and AW267 is not attributable to the reduction in the transcription of the
ply gene when spxB is deleted from the chromosome. This appears to concur with
previous data showing that the location of pneumococcal growth causes no significant
difference in the transcription of ply in vivo (27). This could indicate that spxB is acting
as an oxygen dependent switch for the release of PLY, for example with the organism
releasing more PLY in areas where high amounts of oxygen are available for the
organism, like the nasopharynx, where PLY could aid in colonization via biofilm
formation (30).
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Removal of extracellular H2O2 via catalase only appears to significantly reduce
the amount of PLY released by the pneumococcus in the strain WU2. This effect does not
appear for T4, T4R, or AW267. This seems to indicate that the location of the action of
H2O2 could vary in a strain dependent manner. In order to investigate if pneumococcal
H2O2 was leading to a loss of membrane potential, and thus leakiness that could be
responsible for the release of PLY, we utilized the JC-1 ratiometric dye. However,
preliminary data from the JC-1 ratiometric potential assay (Appendix 3) appears to
indicate that perhaps the 1 hour time of application of H2O2 was insufficient to achieve
the membrane depolarization that could be attributable to release. The data found in this
preliminary JC-1 assay appears to indicate that wild-type strains undergo a loss of
membrane potential that is not seen in the ∆spxB mutants, indicating that pneumococcal
H2O2 could be the cause. However, these findings still need to be verified by a secondary
method like DiBAC3(4), another potentiometric dye, and Propidium iodide, a cell
permeability dye. Future investigation could likely increase the concentration of H2O2
supplemented to the bacteria as the non-lethality of the H2O2 was confirmed via serial
dilution plate counts before and after supplementation with H2O2 (Appendix 2).
Finally, it appears that differences in autolysis are not a likely explanation for the
increased amount of PLY found in the supernatant for the wild type. No difference in the
rate of autolysis was observed when T4R and T4R∆spxB was treated with 0.1% Triton X100. Additionally, no difference was observed in the amount of DNA observed in the
supernatant, which we expect would only be detected due to autolysis.
These findings are interesting since PLY is not the only protein that is excreted by
the pneumococcus without a transport sequence. The literature has previously indicated
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that both enolase and GAPDH/SDH are proteins that can be exported to the exterior of
the pneumococcus without any discernable N-terminal secretion signal (28, 29). It would
be interesting to investigate if the potential mechanism that has been elucidated in this
investigation would apply to the secretion of these proteins as well. As it appears that the
mechanism is conserved across a variety of pneumococcal strains. Furthermore, the
ubiquity of this method of release would be interesting to investigate in other organisms
that produce H2O2 as a potentially generalized mechanism of protein release. Finally,
considering that pyruvate oxidase would be more utilized in an aerobic environment such
as the nasopharynx, considering the importance of biofilm formation for colonization of
the nasopharynx, and the positive relationship of PLY on the formation of biofilms, this
could potentially be a way for the pneumococcus to control the amount of PLY that is
released in an oxygen dependent manner (30, 31).
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CHAPTER III
CONCLUSION

The pneumococcus is a major human pathogen causing significant morbidity and
mortality worldwide (1). It is the causative agent of a number of invasive human diseases
such as bacteremia, septicemia, otitis media, meningitis, and pneumonia (1, 2). Despite
this major impact on human health, however, pneumococcus is carried as a commensal
organism in the nasopharynx in up to 70% of individuals, depending on the population
(3). A better understanding of how the organism is able to utilize the myriad of virulence
factors that it is capable of expressing is important to developing future treatments for
pneumococcal disease, and reducing its burden on health care systems worldwide.
The literature review presented in the first chapter of this thesis examined the role
that Streptococcus pneumoniae plays in human health as a major causative agent of
disease when the immune system becomes compromised (4). An important aspect of the
pneumococcus’ ability to cause disease is its wide range of virulence factors that it
possesses. Our work focused on two virulence factors in particular, pyruvate oxidase and
pneumolysin (PLY). Pyruvate oxidase is an enzyme that allows for the aerobic
metabolism of pyruvate in order to phosphorylate ADP to produce ATP (5). Through the
activity of this enzyme, the pneumococcus is capable of producing up to millimolar
concentrations of H2O2. This is significant as the organism is catalase negative and thus
has limited capacity to neutralize the H2O2 that is produced as a byproduct (6). However,
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expression of pyruvate oxidase is seen to confer a strong competitive advantage to the
pneumococcus in the nasopharynx, allowing it to outcompete other potential inhabitants
by exploiting their sensitivity to hydrogen peroxide (7, 8). Additionally, removal of
pyruvate oxidase appears to attenuate virulence in mouse models and confer resistance to
killing by H2O2 (9, 10). Pneumococcal H2O2 also acts as a potent virulence factor for host
cells, causing necrosis, apoptosis, and DNA damage (15, 16).
In addition to pyruvate oxidase, the pneumococcus possesses another virulence
factor, the 53-kDa cholesterol dependent pore forming cytolysin, pneumolysin (11).
While this toxin acts on host cells extracellularly, it is not well characterized how this
protein is secreted from the bacteria (12–14). A number of mechanisms have been
observed, such as autolysis via lytA releasing intracellular products through breaking
down the cell wall, competence induced fratricide of non-competent cells, and other
release that is not attributable to the activity of lytA (17–19). Based on the autolytic effect
of pyruvate oxidase activity, we investigated a potential link between H2O2 production
and PLY release in pneumococcus.
Chapter 2 summarizes our findings determining the impact of pyruvate oxidase on
the release of PLY in the pneumococcus. Initially, the impact of the deletion of spxB
from the chromosome on the release of PLY to the extracellular space was investigated.
Removal of spxB was found to greatly attenuate the amount of H2O2 found in the
supernatant. Strains WU2, AW267, and T4 with deletion of spxB, resulted in a significant
(p<0.005) reduction in the amount of PLY detected via western blot. Additionally, a
significant (p<0.05) reduction was also observed in T4R, indicating that this mechanism
of release could be general and likely is not specific to only a few strains. Also, deletion
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of spxB greatly reduced the amount of H2O2 produced in vitro. After this finding, the
relevance of this effect was investigated in a panel of 15 clinical isolates obtained from
St. Jude’s Children’s Hospital. Results showed that there was a significant correlation
(p<0.05, r2=.3167) between the amount of PLY released (quantitated via dot blot) and
H2O2 produced when normalized to bacterial counts. This further supports the evidence
obtained through the deletion of the spxB gene. Analysis of the transcription of the ply
gene when spxB was deleted in AW267, WU2, and T4R indicated that in each case,
transcription of the ply gene was upregulated (WU2∆spxB = 1.96 fold, AW267∆spxB =
2.83 fold, and T4R∆spxB = 2.3 fold). This confirmed that the reduction in PLY release
observed upon the deletion of the spxB gene was not due to altered expression of Ply but
was indeed due to abrogated PLY release into the extracellular space. Additionally,
supplementation of 500µM H2O2 to T4R∆spxB for 1 hour resulted in a 1.45 fold
upregulation of the ply gene, indicating that exogenously supplemented H2O2 had no
significant impact upon ply transcription.
In order to ascertain if H2O2 acts extracellularly, we treated wild type strains with
catalase and found a significant reduction in the amount of PLY released (p<0.05) in the
strain WU2. However, this effect was not observed in any other strain, indicating that the
mechanism by which H2O2 acts could potentially be variable. Finally the impact of H2O2
upon the membrane potential of the pneumococcus was investigated utilizing the JC-1
ratiometric membrane potential dye. This study was conducted in order to determine
whether pneumococcal hydrogen peroxide could be reducing membrane potential,
leading to the cell becoming leaky with release of intracellular components. The results
from the preliminary assay suggest that T4R experiences a drop in membrane potential
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after 1 hour of growth that was not seen in T4R∆spxB. Additionally, a similar loss of
membrane potential was observed in T4R∆spxB treated with 1 mM H2O2 at the 1 hour
time point as well. While this preliminary data indicates that pneumococcal H2O2 could
be causing the membrane to become leaky, the findings need to be confirmed with a
second assay utilizing DiBAC3(4), another potentiometric dye, and Propidium Iodide, a
cell impermeable dye to determine if the findings are accurate. Finally, autolysis was
ruled out as a cause for the difference in release between the mutant and wild type as no
discernable difference in autolysis was found in T4R and T4R∆spxB.
In this work, a novel mechanism of transport for intracellular proteins to the
extracellular space in Streptococcus pneumoniae has been identified. Future directions
would determine whether spxB complementation of mutant strains would restore the
capacity to release PLY. This has currently been achieved in strains T4R∆spxB and
T4∆spxB through ligating the SpxB gene to the PNE-1 pneumococcal shuttle vector.
However, analysis of the nature of the complemented strain’s PLY release has not yet
been analyzed. Further research on this mechanism could also lead to insights into
mechanisms that block PLY release in the pneumococcus and attenuate virulence, leading
to new treatments for pneumococcal disease. Additionally, this mechanism should be of
interest for other proteins that are secreted by the pneumococcus but lack secretion
signals, such as enolase and GAPDH/SDH, as it would be interesting to investigate how
the impairing H2O2 expression impacts the secretion of these proteins. (20, 21) Even
more significant would be the application of this mechanism of transport to other H2O2
producing bacteria, to determine whether this could potentially have applications in other
organisms.
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SUPPLEMENTAL DATA

46

Figure A.1

Correlation of H2O2 produced and PLY released in unfiltered clinical
supernatants

This figure represents previously collected clinical data, wherein a stronger correlation
was observed with unfiltered supernatants. This graph represents a significant correlation
(p<0.0001, r2=0.56, n=21) between H2O2 per 100,000 cells, and PLY per 100,000 cells.

Figure A.2

Cell counts following H2O2 treatment

Plate counts of T4R∆spxB were performed before and after incubation with H2O2 at the
specified concentrations for 1 hour on ice. No significant difference was observed
between any concentration of H2O2 and the untreated wild type.
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Figure A.3

JC-1 Ratiometric Analysis of T4R

A ratiometric analysis was used as an attempt to assess membrane potential. This data
appears to suggest a difference in membrane permeability between the mutant when
compared to the wild type and the mutant supplemented with catalase.
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Figure A.4

Bacterial counts

Bacterial counts at 0.5 are shown for AW267 (Appendix 4A), WU2 (Appendix 4B), T4
(Appendix 4C), and T4R (Appendix 4D) with their respective ∆spxB mutants with and
without 10µg of catalase added. Bacteria were serially diluted to determine original
concentration. This data indicates that there is no significant difference in bacterial counts
for each of the strains investigated. The data shown is an average of 3 experiments each
plus and minus the standard deviation for each data set.
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Figure A.5

DNA quantitation

The fluorometric quantitation of the DNA contained in the sterile supernatant of T4R and
T4R∆spxB at OD 0.5. No significant difference was observed between the two, indicating
no significant difference in autolysis. This figure represents 3 indpendent experiments,
plus and minus the standard deviation of the average value.

Figure A.6

Assessment of autolysis by DOC

Quantitation of the difference of autolysis in T4R and T4R∆spxB following
supplementation with 0.05% deoxycholate at OD 0.5 in THY media.
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